UroGen Pharma Ltd.
URGN
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase IIIā¦ read more
Healthcare
Biotechnology
9 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$38.24
Price-6.94%
-$2.85
1Y
Price
Market Cap
$1.863b
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-37.3%
EBITDA Margin-46.3%
Net Profit Margin-89.0%
Free Cash Flow Margin-37.3%
EBITDA Margin-46.3%
Net Profit Margin-89.0%
Free Cash Flow MarginRevenue
$140.493m
+28.0%
1y CAGR+19.6%
3y CAGR+21.8%
5y CAGREarnings
-$133.225m
+13.2%
1y CAGR-10.6%
3y CAGR-6.2%
5y CAGREPS
-$2.75
+13.8%
1y CAGR+7.6%
3y CAGR+12.1%
5y CAGRBook Value
-$124.253m
$253.690m
Assets$377.943m
Liabilities$197.093m
DebtDebt to Assets
77.7%
-1.7x
Debt to EBITDAFree Cash Flow
-$166.035m
-2.0%
1y CAGR-32.1%
3y CAGR-20.9%
5y CAGRNo items found.
Press Releases
Statements and updates from the company